# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)

> **NCT00790556** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** MK8245
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00790556
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790556, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00790556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*